Kennedy Capital Management’s Immunome IMNM Stock Holding History

Kennedy Capital Management’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.87M	Sell	277,064 -9,966	-3%	-$213K	0.1%	297
2026 Q1	$6.28M	Buy	287,030 +675	+0.2%	+$15K	0.13%	242
2025 Q4	$6.15M	Buy	286,355 +28,929	+11%	+$508K	0.13%	254
2025 Q3	$3.01M	Buy	257,426 +148,074	+135%	+$1.47M	0.07%	381
2025 Q2	$1.02M	Buy	109,352 +94,627	+643%	+$776K	0.02%	505
2025 Q1	$99.1K	Buy	14,725 +204	+1%	+$1.96K	﹤0.01%	636
2024 Q4	$154K	Buy	+14,521	New	+$175K	﹤0.01%	664

Other funds holding IMNM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Kennedy Capital Management's IMNM Position: Q2 2026 in Review

Kennedy Capital Management reduced its Immunome (IMNM) stake by 3.5% in Q2 2026, selling an estimated $213K and leaving 277,064 shares worth $5.87M. The position accounts for 0.1% of the portfolio, ranked #297.

Kennedy Capital Management first reported a position in IMNM in Q4 2024 and has held it in 7 quarters since. The position peaked at $6.28M in Q1 2026. 203 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

Kennedy Capital Management held 277,064 shares of Immunome worth $5.87M as of Q2 2026.
Kennedy Capital Management sold 9,966 Immunome shares in Q2 2026, an estimated $213K.
Immunome made up 0.1% of Kennedy Capital Management's portfolio in Q2 2026, its #297 holding.
Kennedy Capital Management first reported a position in Immunome in Q4 2024 and has held it in 7 quarters since.
Kennedy Capital Management's Immunome position peaked at $6.28M in Q1 2026.
203 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Kennedy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.